Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants

MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients

(2020) Brian G. Hunt et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand‐based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase

(2020) Omid Zarei et al.   Molecular Informatics

RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells

(2017) Binbin Yin et al.   ONCOLOGY REPORTS

A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells

(2017) Yu Ling et al.   Oncotarget

Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets

(2015) Katherine Chang et al.   Oncotarget

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

(2015) Parag P. Patwardhan et al.   Oncotarget

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

(2014) C. Feneyrolles et al.   MOLECULAR CANCER THERAPEUTICS

From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer

(2012) Isabelle Dussault et al.   Anti-Cancer Agents in Medicinal Chemistry

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

(2012) S. Betty Yan et al.   INVESTIGATIONAL NEW DRUGS

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors

(2010) Stéphane Raeppel et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

(2009) Gretchen M. Schroeder et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo

(2008) Y. Zhang et al.   CANCER RESEARCH

The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer

(2008) Chung-Ta Lee et al.   DISEASES OF THE COLON & RECTUM

Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract

(2008) E. Compérat et al.   JOURNAL OF UROLOGY